The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT03440372




Registration number
NCT03440372
Ethics application status
Date submitted
14/02/2018
Date registered
22/02/2018
Date last updated
22/06/2020

Titles & IDs
Public title
Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
Scientific title
Induction Study #1 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
Secondary ID [1] 0 0
U1111-1203-7225
Secondary ID [2] 0 0
RPC01-3201
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Crohn Disease 0 0
Condition category
Condition code
Oral and Gastrointestinal 0 0 0 0
Inflammatory bowel disease
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders
Oral and Gastrointestinal 0 0 0 0
Crohn's disease

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Ozanimod
Other interventions - Placebo

Experimental: Administration of oral Ozanimod - Subjects will receive ozanimod 0.92 mg capsule orally starting with a 7-day dose escalation

Placebo Comparator: Administration of Placebo - Subjects will receive placebo capsule orally starting with a 7-day dose escalation


Treatment: Drugs: Ozanimod
Ozanimod

Other interventions: Placebo
Placebo

Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Proportion of subjects with a CDAI score < 150 - The Crohn's Disease Activity Index (CDAI) is a composite score that is used to measure the clinical activity of CD.
Timepoint [1] 0 0
Week 12
Secondary outcome [1] 0 0
Proportion of subjects with average daily abdominal pain score = 1 point, and average daily stool frequency score = 3 points with abdominal pain and stool frequency no worse than baseline - Abdominal pain scores and stool frequency scores are patient reported outcomes collected from the patient diary.
Timepoint [1] 0 0
Week 12
Secondary outcome [2] 0 0
Proportion of subjects with a Simple Endoscopic Score for Crohn's Disease (SES-CD) score decrease from baseline of = 50% - The SES-CD assesses the degree of inflammation. The SES-CD assesses the following 4 components: size of ulcers, ulcerated surface, affected surface, and presence of narrowing.
Timepoint [2] 0 0
Week 12
Secondary outcome [3] 0 0
Proportion of subjects with CDAI reduction from baseline of = 100 points or CDAI score < 150 - The Crohn's Disease Activity Index (CDAI) is a composite score that is used to measure the clinical activity of CD.
Timepoint [3] 0 0
Week 12
Secondary outcome [4] 0 0
Proportion of subjects with CDAI reduction from baseline of = 100 points or CDAI score < 150 and SES-CD decrease from baseline of = 50% - The Crohn's Disease Activity Index (CDAI) is a composite score that is used to measure the clinical activity of CD and the SES-CD assesses the degree of inflammation.
Timepoint [4] 0 0
Week 12
Secondary outcome [5] 0 0
Proportion of subjects with CDAI score < 150 at Week 12 and SES-CD decrease from baseline of = 50% - The Crohn's Disease Activity Index (CDAI) is a composite score that is used to measure the clinical activity of CD and the SES-CD assesses the degree of inflammation.
Timepoint [5] 0 0
Week 12
Secondary outcome [6] 0 0
Proportion of subjects with an average daily abdominal pain score = 1 point, and average daily stool frequency score = 3 points and both no worse than baseline AND an SES-CD = 4 points and decrease =2 points at week 12 - Abdominal pain scores and stool frequency scores are patient reported outcomes collected from the patient diary. The SES-CD assesses the degree of inflammation.
Timepoint [6] 0 0
Up to approximately week 12
Secondary outcome [7] 0 0
Proportion of subjects with an average daily abdominal pain score = 1 point, and average daily stool frequency score = 3 points and both no worse than baseline AND an SES-CD decrease from baseline of = 50% at week 12. - Abdominal pain scores and stool frequency scores are patient reported outcomes collected from the patient diary. The SES-CD assesses the degree of inflammation.
Timepoint [7] 0 0
Up to approximately week 12
Secondary outcome [8] 0 0
Histologic Improvement based on differences between ozanimod and placebo in histologic disease activity scores (ie, Global Histologic Disease Activity Score changes (Geboes, 2000) - Global Histologic Disease Activity score is a measure of histologic inflammation.
Timepoint [8] 0 0
Week 12
Secondary outcome [9] 0 0
Proportion of subjects with CDAI reduction from baseline of = 70 points - The Crohn's Disease Activity Index (CDAI) is a composite score that is used to measure the clinical activity of CD.
Timepoint [9] 0 0
Week 12
Secondary outcome [10] 0 0
Proportion of subjects with absence of ulcers = 0.5 cm with no segment with any ulcerated surface = 10% - Ulcer size will be measured during endoscopy, and assesses the degree of endoscopic inflammation.
Timepoint [10] 0 0
Week 12
Secondary outcome [11] 0 0
Proportion of subjects with a Crohn's Disease Endoscopic Index of Severity (CDEIS) decrease from baseline of = 50% - The CDEIS assesses the degree of endoscopic inflammation.
Timepoint [11] 0 0
Week 12
Secondary outcome [12] 0 0
Proportion of adolescent subjects with clinical remission, defined as Pediatric Crohn's Disease Activity Index (PCDAI) = 10 points at week 12 - The PCDAI is an instrument that was developed and validated for numerical assessment of disease activity in children and adolescents with CD (Hyams, 1991). The PCDAI includes subjective patient historical information, physical examination findings, objective laboratory parameters, data on weight gain/loss, and height velocity.
Timepoint [12] 0 0
Up to approximately week 12
Secondary outcome [13] 0 0
Proportion of adolescent subjects with clinical response, defined as a decrease in PCDAI = 15 points from baseline - The PCDAI is an instrument that was developed and validated for numerical assessment of disease activity in children and adolescents with CD (Hyams, 1991). The PCDAI includes subjective patient historical information, physical examination findings, objective laboratory parameters, data on weight gain/loss, and height velocity.
Timepoint [13] 0 0
Up to approximately week 12
Secondary outcome [14] 0 0
Change from baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) scores (adult subjects only) - The IBDQ is a frequently used outcome parameter in clinical trials. The IBDQ is a responsive instrument for reflection quick change in the quality of life of patients with CD, within a 2-week period. The IBDQ has evolved into a standard for measuring disease-specific quality of life in patients with CD.
Timepoint [14] 0 0
Up approximately Week 12
Secondary outcome [15] 0 0
Change from baseline in 36-Item Short Form-36 Survey (SF-36) scores (adult subjects only) - The medical outcomes SF-36 questionnaire provides a measure of the subject's health status.
Timepoint [15] 0 0
Up to approximately week 12
Secondary outcome [16] 0 0
Change from baseline in Work Productivity and Activity Impairment questionnaire for Crohn's disease (WPAI-CD) scores (adult subjects only) - The WPAI-CD is a validated, reliable and responsive instrument that assesses the impact of CD on work and activity.
Timepoint [16] 0 0
Up to approximately week 12
Secondary outcome [17] 0 0
Change from baseline in EuroQol 5 dimensions questionnaire (EQ- 5D) scores - The EQ-5D is a validated, 6-item, self-administered instrument designed to measure generic health status.
Timepoint [17] 0 0
Up to approximately week 12
Secondary outcome [18] 0 0
Differences in CD-related hospitalizations, procedures, and surgery - Healthcare Resource Utilization (HRU) will be evaluated in this study to assess the impact of CD and health-related outcomes (hospitalizations, emergency department or urgent care clinic visits, procedures, and physician visits).
Timepoint [18] 0 0
Week 12
Secondary outcome [19] 0 0
Assessment of circulating lymphocyte concentration - T and B cell panels consisting of Treg cells, naïve T and B cells, memory cells and plasmablasts are evaluated for assessment of immune status.
Timepoint [19] 0 0
Up to approximately week 12
Secondary outcome [20] 0 0
Assessment of gene expression - Interferon signature are assessed in the blood and in colon biopsies to evaluate differences based on disease activity.
Timepoint [20] 0 0
Up to approximately week 12
Secondary outcome [21] 0 0
Assessment of protein biomarker concentration - Protein biomarkers such as high-density lipoprotein, C-reactive protein, fecal calprotectin, Immunoglobulin A (IgA) are measured in addition to assessing clinical endpoints to help evaluate disease activity.
Timepoint [21] 0 0
Up to approximately week 12
Secondary outcome [22] 0 0
Assessment of pharmacogenetics - Markers such as Interferon Regulatory Factor 5 are evaluated to better understand genetic variations that could lead to differences in response to Ozanimod.
Timepoint [22] 0 0
Up to approximately week 12

Eligibility
Key inclusion criteria
Subjects must satisfy the following criteria to be enrolled in the study:

1. Aged 12-75 years 2. Crohn's disease for = 3 months on endoscopy and on histological exam
3. Inadequate response or loss of response to corticosteroids, immunomodulators, and/or
biologic therapy 4. Patient has met each of the following clinical and endoscopic criteria:

1. Crohn's Disease Activity Index (CDAI) score = 220 and = 450.

2. Average daily stool frequency = 4 points and/or an abdominal pain of = 2 points.

3. SES-CD score of = 6 (or SES-CD = 4 in subjects with isolated ileal disease).
Minimum age
12 Years
Maximum age
75 Years
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
The presence of any of the following will exclude a subject from enrollment or at the time
point specified in the following criteria:

1. Subject has a diagnosis of UC, indeterminate colitis, radiation colitis, or ischemic
colitis, or has strictures with prestenotic dilatation, requiring procedural
intervention, or with obstructive symptoms. In addition, subjects with colonic or
ileal strictures that are not passable with an age-appropriate colonoscope that the
endoscopist normally uses in clinical practice, or strictures in the ileum or
ileocecal valve that are fibrotic in nature, will be excluded.

2. Current stoma, ileal-anal pouch anastomosis, fistula that is likely to require, in the
physician's judgement, surgical or medical intervention within 12 weeks of entry into
the study, or need for ileostomy or colostomy.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,WA
Recruitment hospital [1] 0 0
Concord Repatriation General Hospital - Concord
Recruitment hospital [2] 0 0
Nepean Hospital - Kingswood
Recruitment hospital [3] 0 0
Wollongong Hospital - Wollongong
Recruitment hospital [4] 0 0
Princess Alexandra Hospital - Woolloongabba
Recruitment hospital [5] 0 0
Royal Adelaide Hospital - Adelaide
Recruitment hospital [6] 0 0
The Queen Elizabeth Hospital - Woodville South
Recruitment hospital [7] 0 0
Harry Perkins Medical Research Institute, Fiona Stanley Hospital - Murdoch
Recruitment hospital [8] 0 0
Ballarat Base Hospital - Ballarat
Recruitment postcode(s) [1] 0 0
2139 - Concord
Recruitment postcode(s) [2] 0 0
2747 - Kingswood
Recruitment postcode(s) [3] 0 0
2500 - Wollongong
Recruitment postcode(s) [4] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [5] 0 0
5000 - Adelaide
Recruitment postcode(s) [6] 0 0
5011 - Woodville South
Recruitment postcode(s) [7] 0 0
6150 - Murdoch
Recruitment postcode(s) [8] 0 0
3350 - Ballarat
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Arkansas
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Connecticut
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Georgia
Country [8] 0 0
United States of America
State/province [8] 0 0
Illinois
Country [9] 0 0
United States of America
State/province [9] 0 0
Iowa
Country [10] 0 0
United States of America
State/province [10] 0 0
Kentucky
Country [11] 0 0
United States of America
State/province [11] 0 0
Louisiana
Country [12] 0 0
United States of America
State/province [12] 0 0
Maryland
Country [13] 0 0
United States of America
State/province [13] 0 0
Massachusetts
Country [14] 0 0
United States of America
State/province [14] 0 0
Michigan
Country [15] 0 0
United States of America
State/province [15] 0 0
Mississippi
Country [16] 0 0
United States of America
State/province [16] 0 0
Missouri
Country [17] 0 0
United States of America
State/province [17] 0 0
New Jersey
Country [18] 0 0
United States of America
State/province [18] 0 0
New Mexico
Country [19] 0 0
United States of America
State/province [19] 0 0
New York
Country [20] 0 0
United States of America
State/province [20] 0 0
North Carolina
Country [21] 0 0
United States of America
State/province [21] 0 0
Ohio
Country [22] 0 0
United States of America
State/province [22] 0 0
Oklahoma
Country [23] 0 0
United States of America
State/province [23] 0 0
Oregon
Country [24] 0 0
United States of America
State/province [24] 0 0
Pennsylvania
Country [25] 0 0
United States of America
State/province [25] 0 0
Tennessee
Country [26] 0 0
United States of America
State/province [26] 0 0
Texas
Country [27] 0 0
United States of America
State/province [27] 0 0
Utah
Country [28] 0 0
United States of America
State/province [28] 0 0
Virginia
Country [29] 0 0
United States of America
State/province [29] 0 0
Washington
Country [30] 0 0
United States of America
State/province [30] 0 0
Wisconsin
Country [31] 0 0
Argentina
State/province [31] 0 0
Ciudad Autonoma de Buenos Aires
Country [32] 0 0
Argentina
State/province [32] 0 0
Cordoba
Country [33] 0 0
Argentina
State/province [33] 0 0
Rosario
Country [34] 0 0
Argentina
State/province [34] 0 0
San Miguel de Tucuman
Country [35] 0 0
Belarus
State/province [35] 0 0
Grodno
Country [36] 0 0
Belarus
State/province [36] 0 0
Vitebsk
Country [37] 0 0
Belgium
State/province [37] 0 0
Brasschaat
Country [38] 0 0
Belgium
State/province [38] 0 0
Brussels
Country [39] 0 0
Belgium
State/province [39] 0 0
Edegem
Country [40] 0 0
Belgium
State/province [40] 0 0
Ghent
Country [41] 0 0
Belgium
State/province [41] 0 0
Leuven
Country [42] 0 0
Belgium
State/province [42] 0 0
Liege
Country [43] 0 0
Belgium
State/province [43] 0 0
Seraing
Country [44] 0 0
Belgium
State/province [44] 0 0
Tournai
Country [45] 0 0
Bosnia and Herzegovina
State/province [45] 0 0
Banja Luka
Country [46] 0 0
Bosnia and Herzegovina
State/province [46] 0 0
Mostar
Country [47] 0 0
Bosnia and Herzegovina
State/province [47] 0 0
Sarajevo
Country [48] 0 0
Bulgaria
State/province [48] 0 0
Plovdiv
Country [49] 0 0
Bulgaria
State/province [49] 0 0
Sofia
Country [50] 0 0
Bulgaria
State/province [50] 0 0
Varna
Country [51] 0 0
Canada
State/province [51] 0 0
Alberta
Country [52] 0 0
Canada
State/province [52] 0 0
British Columbia
Country [53] 0 0
Canada
State/province [53] 0 0
Manitoba
Country [54] 0 0
Canada
State/province [54] 0 0
Nova Scotia
Country [55] 0 0
Canada
State/province [55] 0 0
Ontario
Country [56] 0 0
Croatia
State/province [56] 0 0
Osijek
Country [57] 0 0
Croatia
State/province [57] 0 0
Rijeka
Country [58] 0 0
Croatia
State/province [58] 0 0
Split
Country [59] 0 0
Croatia
State/province [59] 0 0
Zagreb
Country [60] 0 0
Czechia
State/province [60] 0 0
Brno
Country [61] 0 0
Czechia
State/province [61] 0 0
Hradec Králové
Country [62] 0 0
Czechia
State/province [62] 0 0
Most
Country [63] 0 0
Czechia
State/province [63] 0 0
Olomouc
Country [64] 0 0
Czechia
State/province [64] 0 0
Pardubice
Country [65] 0 0
Czechia
State/province [65] 0 0
Plzen
Country [66] 0 0
Czechia
State/province [66] 0 0
Prague 5
Country [67] 0 0
Czechia
State/province [67] 0 0
Prague 9
Country [68] 0 0
Czechia
State/province [68] 0 0
Praha 4
Country [69] 0 0
Denmark
State/province [69] 0 0
Copenhagen
Country [70] 0 0
Denmark
State/province [70] 0 0
Holbaek
Country [71] 0 0
Denmark
State/province [71] 0 0
Nykobing F
Country [72] 0 0
France
State/province [72] 0 0
Amiens cedex 1
Country [73] 0 0
France
State/province [73] 0 0
Creteil Cedex
Country [74] 0 0
France
State/province [74] 0 0
Dijon Cedex
Country [75] 0 0
France
State/province [75] 0 0
Grenoble Cedex 9
Country [76] 0 0
France
State/province [76] 0 0
Lillie Cedex
Country [77] 0 0
France
State/province [77] 0 0
Marseille cedex 20
Country [78] 0 0
France
State/province [78] 0 0
Rennes
Country [79] 0 0
France
State/province [79] 0 0
Rouen Cedex
Country [80] 0 0
France
State/province [80] 0 0
Toulouse Cedex 09
Country [81] 0 0
Germany
State/province [81] 0 0
Berlin
Country [82] 0 0
Germany
State/province [82] 0 0
Frankfurt
Country [83] 0 0
Germany
State/province [83] 0 0
Hamburg
Country [84] 0 0
Germany
State/province [84] 0 0
Leipzig
Country [85] 0 0
Germany
State/province [85] 0 0
Ludwigshafen am Rhein
Country [86] 0 0
Germany
State/province [86] 0 0
Munich
Country [87] 0 0
Germany
State/province [87] 0 0
Tuebingen
Country [88] 0 0
Germany
State/province [88] 0 0
Ulm
Country [89] 0 0
Ireland
State/province [89] 0 0
Dublin
Country [90] 0 0
Ireland
State/province [90] 0 0
Dublin 9
Country [91] 0 0
Israel
State/province [91] 0 0
Bat Yam
Country [92] 0 0
Israel
State/province [92] 0 0
Jerusalem
Country [93] 0 0
Israel
State/province [93] 0 0
Nahariya
Country [94] 0 0
Israel
State/province [94] 0 0
Nazareth
Country [95] 0 0
Israel
State/province [95] 0 0
Ramat Gan
Country [96] 0 0
Israel
State/province [96] 0 0
Rechovot
Country [97] 0 0
Italy
State/province [97] 0 0
Bari
Country [98] 0 0
Italy
State/province [98] 0 0
Bologna
Country [99] 0 0
Italy
State/province [99] 0 0
Brescia
Country [100] 0 0
Italy
State/province [100] 0 0
Castellana Grotte
Country [101] 0 0
Italy
State/province [101] 0 0
Catanzaro
Country [102] 0 0
Italy
State/province [102] 0 0
Chieti
Country [103] 0 0
Italy
State/province [103] 0 0
Messina
Country [104] 0 0
Italy
State/province [104] 0 0
Milano
Country [105] 0 0
Italy
State/province [105] 0 0
Milan
Country [106] 0 0
Italy
State/province [106] 0 0
Monza
Country [107] 0 0
Italy
State/province [107] 0 0
Padova
Country [108] 0 0
Italy
State/province [108] 0 0
Palermo
Country [109] 0 0
Italy
State/province [109] 0 0
Pavia
Country [110] 0 0
Italy
State/province [110] 0 0
Roma
Country [111] 0 0
Italy
State/province [111] 0 0
Rome
Country [112] 0 0
Italy
State/province [112] 0 0
Udine
Country [113] 0 0
Italy
State/province [113] 0 0
Varese
Country [114] 0 0
Italy
State/province [114] 0 0
Verona
Country [115] 0 0
Korea, Republic of
State/province [115] 0 0
Ansan
Country [116] 0 0
Korea, Republic of
State/province [116] 0 0
Guri-si
Country [117] 0 0
Korea, Republic of
State/province [117] 0 0
Seongnam-si
Country [118] 0 0
Korea, Republic of
State/province [118] 0 0
Seoul
Country [119] 0 0
Latvia
State/province [119] 0 0
Riga
Country [120] 0 0
Mexico
State/province [120] 0 0
Jalisco
Country [121] 0 0
Mexico
State/province [121] 0 0
Nuevo León
Country [122] 0 0
Mexico
State/province [122] 0 0
Querétaro
Country [123] 0 0
Mexico
State/province [123] 0 0
Chihuahua
Country [124] 0 0
Mexico
State/province [124] 0 0
Mexico
Country [125] 0 0
Mexico
State/province [125] 0 0
Tlalpan
Country [126] 0 0
Moldova, Republic of
State/province [126] 0 0
Chisinau
Country [127] 0 0
Norway
State/province [127] 0 0
Lørenskog
Country [128] 0 0
Norway
State/province [128] 0 0
Oslo
Country [129] 0 0
Poland
State/province [129] 0 0
Bialystok
Country [130] 0 0
Poland
State/province [130] 0 0
Bochnia
Country [131] 0 0
Poland
State/province [131] 0 0
Katowice
Country [132] 0 0
Poland
State/province [132] 0 0
Klodzko
Country [133] 0 0
Poland
State/province [133] 0 0
Krakow
Country [134] 0 0
Poland
State/province [134] 0 0
Lodz
Country [135] 0 0
Poland
State/province [135] 0 0
Lublin
Country [136] 0 0
Poland
State/province [136] 0 0
Olsztyn
Country [137] 0 0
Poland
State/province [137] 0 0
Poznan
Country [138] 0 0
Poland
State/province [138] 0 0
Torun
Country [139] 0 0
Poland
State/province [139] 0 0
Tychy
Country [140] 0 0
Poland
State/province [140] 0 0
Ul. Piotrkowska 177
Country [141] 0 0
Poland
State/province [141] 0 0
Warsaw
Country [142] 0 0
Poland
State/province [142] 0 0
Warszawa
Country [143] 0 0
Romania
State/province [143] 0 0
Bucharest
Country [144] 0 0
Romania
State/province [144] 0 0
Craiova
Country [145] 0 0
Romania
State/province [145] 0 0
Napoca
Country [146] 0 0
Romania
State/province [146] 0 0
Targu Mures
Country [147] 0 0
Russian Federation
State/province [147] 0 0
Chita
Country [148] 0 0
Russian Federation
State/province [148] 0 0
Irkutsk
Country [149] 0 0
Russian Federation
State/province [149] 0 0
Kazan
Country [150] 0 0
Russian Federation
State/province [150] 0 0
Khanty-mansiysk
Country [151] 0 0
Russian Federation
State/province [151] 0 0
Krasnoyarsk
Country [152] 0 0
Russian Federation
State/province [152] 0 0
Moscow
Country [153] 0 0
Russian Federation
State/province [153] 0 0
Novosibirsk
Country [154] 0 0
Russian Federation
State/province [154] 0 0
Petrozavodsk
Country [155] 0 0
Russian Federation
State/province [155] 0 0
Pushkin
Country [156] 0 0
Russian Federation
State/province [156] 0 0
Pyatigorsk
Country [157] 0 0
Russian Federation
State/province [157] 0 0
Rostov-on-Don
Country [158] 0 0
Russian Federation
State/province [158] 0 0
Saint Petersburg
Country [159] 0 0
Russian Federation
State/province [159] 0 0
Samara
Country [160] 0 0
Russian Federation
State/province [160] 0 0
St Petersburg
Country [161] 0 0
Russian Federation
State/province [161] 0 0
St. Petersburg
Country [162] 0 0
Russian Federation
State/province [162] 0 0
Surgut
Country [163] 0 0
Russian Federation
State/province [163] 0 0
Tula
Country [164] 0 0
Russian Federation
State/province [164] 0 0
Ufa
Country [165] 0 0
Russian Federation
State/province [165] 0 0
Ulyanovsk
Country [166] 0 0
Russian Federation
State/province [166] 0 0
Veliky Novgorod
Country [167] 0 0
Russian Federation
State/province [167] 0 0
Vladimir
Country [168] 0 0
Russian Federation
State/province [168] 0 0
Vladivostok
Country [169] 0 0
Saudi Arabia
State/province [169] 0 0
Dammam
Country [170] 0 0
Saudi Arabia
State/province [170] 0 0
Jeddah
Country [171] 0 0
Saudi Arabia
State/province [171] 0 0
Riyadh
Country [172] 0 0
Spain
State/province [172] 0 0
Alicante
Country [173] 0 0
Spain
State/province [173] 0 0
Badalona
Country [174] 0 0
Spain
State/province [174] 0 0
La Laguna
Country [175] 0 0
Spain
State/province [175] 0 0
Madrid
Country [176] 0 0
Spain
State/province [176] 0 0
Sevilla
Country [177] 0 0
Spain
State/province [177] 0 0
Viladecans
Country [178] 0 0
Switzerland
State/province [178] 0 0
Bern
Country [179] 0 0
Switzerland
State/province [179] 0 0
St.Gallen
Country [180] 0 0
Switzerland
State/province [180] 0 0
Zurich
Country [181] 0 0
Taiwan
State/province [181] 0 0
Kozlu
Country [182] 0 0
Turkey
State/province [182] 0 0
Ankara
Country [183] 0 0
Turkey
State/province [183] 0 0
Bursa
Country [184] 0 0
Turkey
State/province [184] 0 0
Istanbul
Country [185] 0 0
Turkey
State/province [185] 0 0
Kocaeli
Country [186] 0 0
Turkey
State/province [186] 0 0
Trabzon
Country [187] 0 0
Ukraine
State/province [187] 0 0
Chernivtsi
Country [188] 0 0
Ukraine
State/province [188] 0 0
Dnipropetrovsk
Country [189] 0 0
Ukraine
State/province [189] 0 0
Ivano-Frankivsk
Country [190] 0 0
Ukraine
State/province [190] 0 0
Kharkiv
Country [191] 0 0
Ukraine
State/province [191] 0 0
Kyiv
Country [192] 0 0
Ukraine
State/province [192] 0 0
Lviv
Country [193] 0 0
Ukraine
State/province [193] 0 0
Poltava
Country [194] 0 0
Ukraine
State/province [194] 0 0
Ternopil
Country [195] 0 0
Ukraine
State/province [195] 0 0
Vinnytsia
Country [196] 0 0
Ukraine
State/province [196] 0 0
Zhytomyr
Country [197] 0 0
United Kingdom
State/province [197] 0 0
Birmingham
Country [198] 0 0
United Kingdom
State/province [198] 0 0
Bristol
Country [199] 0 0
United Kingdom
State/province [199] 0 0
Dundonald
Country [200] 0 0
United Kingdom
State/province [200] 0 0
Glasgow
Country [201] 0 0
United Kingdom
State/province [201] 0 0
Lancashire Blackpool
Country [202] 0 0
United Kingdom
State/province [202] 0 0
London
Country [203] 0 0
United Kingdom
State/province [203] 0 0
Oxford
Country [204] 0 0
United Kingdom
State/province [204] 0 0
Sheffield
Country [205] 0 0
United Kingdom
State/province [205] 0 0
Southampton
Country [206] 0 0
United Kingdom
State/province [206] 0 0
Torquay

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Celgene
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a Phase 3, randomized, double-blind, placebo-controlled study to explore the effect
of oral ozanimod as an induction treatment for subjects with moderately to severely active
Crohn's Disease.
Trial website
https://clinicaltrials.gov/show/NCT03440372
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Kanthi Kollengode, MD
Address 0 0
Celgene Corporation
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Associate Director Clinical Trial Disclosure
Address 0 0
Country 0 0
Phone 0 0
1-888-260-1599
Fax 0 0
Email 0 0
clinicaltrialdisclosure@celgene.com
Contact person for scientific queries

Summary results
For IPD and results data, please see https://clinicaltrials.gov/show/NCT03440372